Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has extended its distributor agreement in Japan with Northern Science Consulting for Monolix.

Jonathan Chauvin, President of the Lixoft division, said: “We are excited to be partnering with Northern Science Consulting to further serve the needs of the Japanese scientific markets. We already have a large community of users in Japan, from hospitals to domestic companies, and we have been encouraged by the response to our technology. The Japanese market is quite mature. We see this as the most opportune time to have a local presence in Japan to increase awareness of Monolix while also strengthening the relationships we have already formed with Japanese companies and universities. We are pleased with this agreement as Northern Science Consulting is a well-recognized company in Japan and is already successful in distributing Simulations Plus.”

This distribution agreement for MonolixSuite® will complement the existing arrangement between Simulations Plus and Northern Science Consulting, the distributor for the Company’s software products, including GastroPlus and ADMET Predictor, thereby expanding the Company’s reach across discovery, pre-clinical and clinical research and development within the Japanese pharmaceutical industry.

Goh Murakami, Chief Executive Officer at Northern Science Consulting Inc., said: “Founded in 2004, Northern Science Consulting in Japan strongly supports biological science research and development through the provision and support of software. There are many customers, mainly in the laboratories of pharmaceutical companies. We look forward to extending the Simulations Plus relationship with the Lixoft division.”

About Simulations Plus, Inc.

Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | Read our Environmental, Social, and Governance (ESG) Report.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005354/en/